HIV 관련 간 병인을 위한 이중 인간화 TK-NOG 마우스 모델 구축

Executive Industry Relevance

The dual humanized TK-NOG mouse model enables mechanistic de-risking of HIV-associated liver pathogenesis by recapitulating human hepatocyte engraftment and immune system development. This system supports target validation and preclinical evaluation of antiviral and antiretroviral compounds in a disease-relevant context. It provides predictive confidence for translational biomarker alignment and portfolio triage in infectious disease programs.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Interrogates therapeutic hypotheses on HIV-induced liver immunopathology using human hepatocytes and immune cells.
• Operational Value: Enables functional target validation through measurable human albumin levels and immune cell reconstitution.
• Predictive Value: Supports preclinical model selection by demonstrating liver damage phenotypes comparable to HIV-infected patients.

Screening & Assay Development

• Scientific Value: Prepares validated biological systems for downstream antiviral compound screening with quantifiable human-specific albumin ELISA readouts.
• Operational Value: Standardizes engraftment assessment via monthly human albumin ELISA and immune cell flow cytometry for reproducible monitoring.
• Scalability Value: Facilitates platform reuse across hepatitis virus co-infection studies and therapeutic intervention evaluations.

Translational & Preclinical Research

• Scientific Value: Models disease-relevant liver immunopathology to bridge discovery findings with preclinical validation of HIV pathogenesis mechanisms.
• Operational Value: Enables risk-adjusted advancement decisions by monitoring human CK18+ hepatocyte depletion and CD4/CD8 ratio shifts post-infection.
• Translational Continuity: Supports evaluation of antiviral compounds in a system exhibiting physiological aspects of human liver and immune function.

Pipeline & Workflow Integration

The model integrates into the discovery continuum from target validation through lead identification to preclinical efficacy testing, particularly for HIV-associated liver disease and co-infection studies.

• Discovery Biology: Supports hypothesis testing of HIV-driven liver damage via human hepatocyte and immune cell engraftment in immunodeficient mice.
• Screening: Delivers assay readiness through quantifiable human albumin levels and immune cell profiling for compound evaluation.
• Analytics: Provides quantitative dependent variable measurements (human albumin ELISA, flow cytometry) enabling cross-condition comparison and effect size determination.
• Translational Research: Connects to preclinical continuity by modeling liver damage and immune dysregulation observed in HIV-infected patients.
• Enterprise Reuse: Serves as a reusable capability for studying hepatitis virus co-infection and antiviral drug efficacy across multiple projects.

Operational & Enterprise Impact

• Scientific Value: Reduces mechanistic ambiguity in HIV liver pathogenesis through dual reconstitution of human liver and immune compartments.
• Operational Value: Ensures standardization and reproducibility via defined engraftment thresholds (>15% human CD45+ cells, detectable human albumin).
• Strategic Value: Improves go/no-go decisions by enabling early detection of hepatocyte depletion and immune dysregulation.
• Portfolio Impact: Informs risk-adjusted prioritization of antiviral candidates based on liver pathology mitigation in a human-relevant system.

Implementation Considerations

• Requires expertise in hematopoietic stem cell isolation, hepatocyte preparation, and murine surgical procedures.
• Depends on specialized instrumentation including flow cytometers, ELISA readers, and biosafety level two plus facilities.
• Necessitates cross-team standardization of engraftment validation protocols using human albumin ELISA and immune cell flow cytometry.
• Involves adaptation considerations for different donor sources of hepatocytes and HSPCs to maintain engraftment consistency.
• Limited by the need for treosulfan conditioning and ganciclovir administration to achieve dual reconstitution, which adds procedural complexity.

Biopharma FAQs